Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Coleman, Robert L, Brady, Mark F, Herzog, Thomas J, Sabbatini, Paul, Armstrong, Deborah K, Walker, Joan L, Kim, Byoung-Gie, Fujiwara, Keiichi, Tewari, Krishnansu S, O'Malley, David M, Davidson, Susan A, Rubin, Stephen C, DiSilvestro, Paul, Basen-Engquist, Karen, Huang, Helen, Chan, John K, Spirtos, Nick M, Ashfaq, Raheela, Mannel, Robert S
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5715461/
https://ncbi.nlm.nih.gov/pubmed/28438473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30279-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados